The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Subscribe To Our Newsletter & Stay Updated
